# Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.

> **NCT04632199** · PHASE1 · WITHDRAWN · sponsor: **Ipsen**

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** 111In-IPN01087 Low dose
- **DRUG:** 111In-IPN01087 High dose

## Key facts

- **NCT ID:** NCT04632199
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-03-12
- **Primary completion:** 2021-12-10
- **Final completion:** 2021-12-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision not related to any safety or tolerability concern
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04632199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04632199, "Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04632199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*